HU229806B1 - Orally dosable sustained-release compositions of quinolone antibiotics and method for preparation thereof - Google Patents
Orally dosable sustained-release compositions of quinolone antibiotics and method for preparation thereof Download PDFInfo
- Publication number
- HU229806B1 HU229806B1 HU0300953A HUP0300953A HU229806B1 HU 229806 B1 HU229806 B1 HU 229806B1 HU 0300953 A HU0300953 A HU 0300953A HU P0300953 A HUP0300953 A HU P0300953A HU 229806 B1 HU229806 B1 HU 229806B1
- Authority
- HU
- Hungary
- Prior art keywords
- composition according
- lubricant
- acid
- polymer
- active ingredient
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 82
- 238000002360 preparation method Methods 0.000 title claims description 13
- 238000000034 method Methods 0.000 title claims description 12
- 239000003242 anti bacterial agent Substances 0.000 title claims description 3
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical group C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 title claims description 3
- 229940088710 antibiotic agent Drugs 0.000 title claims 2
- 238000013268 sustained release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 title 1
- 239000004480 active ingredient Substances 0.000 claims description 32
- 239000000314 lubricant Substances 0.000 claims description 24
- 229920000642 polymer Polymers 0.000 claims description 20
- 238000004090 dissolution Methods 0.000 claims description 16
- 150000007524 organic acids Chemical class 0.000 claims description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 8
- -1 quinone amide Chemical class 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 6
- 230000003115 biocidal effect Effects 0.000 claims description 5
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 235000005985 organic acids Nutrition 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims description 2
- 229910052623 talc Inorganic materials 0.000 claims description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims 7
- 239000007884 disintegrant Substances 0.000 claims 6
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 2
- 150000007513 acids Chemical class 0.000 claims 2
- 240000003291 Armoracia rusticana Species 0.000 claims 1
- 235000011330 Armoracia rusticana Nutrition 0.000 claims 1
- 108010068370 Glutens Proteins 0.000 claims 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 claims 1
- AHQOXSLIWUYSLL-UHFFFAOYSA-N N1C(C=CC=C1)=O.C=C Chemical group N1C(C=CC=C1)=O.C=C AHQOXSLIWUYSLL-UHFFFAOYSA-N 0.000 claims 1
- KYGZCKSPAKDVKC-UHFFFAOYSA-N Oxolinic acid Chemical class C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC2=C1OCO2 KYGZCKSPAKDVKC-UHFFFAOYSA-N 0.000 claims 1
- 239000004743 Polypropylene Substances 0.000 claims 1
- 244000062793 Sorghum vulgare Species 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 230000000507 anthelmentic effect Effects 0.000 claims 1
- 239000003518 caustics Substances 0.000 claims 1
- 229920003086 cellulose ether Polymers 0.000 claims 1
- 235000021312 gluten Nutrition 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims 1
- 235000019713 millet Nutrition 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 229920001155 polypropylene Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 235000012222 talc Nutrition 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 20
- 239000003826 tablet Substances 0.000 description 19
- 230000003111 delayed effect Effects 0.000 description 15
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000001384 succinic acid Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000002156 mixing Methods 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229920001477 hydrophilic polymer Polymers 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 101710200331 Cytochrome b-245 chaperone 1 Proteins 0.000 description 2
- 102100037186 Cytochrome b-245 chaperone 1 Human genes 0.000 description 2
- 101710119396 Cytochrome b-245 chaperone 1 homolog Proteins 0.000 description 2
- 241001505295 Eros Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 229960003405 ciprofloxacin Drugs 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- DIRFUJHNVNOBMY-UHFFFAOYSA-N fenobucarb Chemical compound CCC(C)C1=CC=CC=C1OC(=O)NC DIRFUJHNVNOBMY-UHFFFAOYSA-N 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- DXIYLWSDOMVIEQ-UHFFFAOYSA-N 3-hydroxypropyl methanesulfonate Chemical compound CS(=O)(=O)OCCCO DXIYLWSDOMVIEQ-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 240000005125 Myrtus communis Species 0.000 description 1
- 235000013418 Myrtus communis Nutrition 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000218657 Picea Species 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 229940088516 cipro Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000008185 minitablet Substances 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000008014 pharmaceutical binder Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
Mennyiség (mg) | Alkaltnazoft anyagok |
360,70 | Clpro Ooxacln bukók fond |
41,70 | Clproöoxaciö betart! |
46,700 | MdonCl** |
4.30 | Aerosi! 200*»*- |
4,70 | ktagrsézium-sztearái |
4Ő4.IÖ | Résrö.wzei; / /A-résr |
302,70 | Cjproilíxacm hiárokiorid |
464,30 | Cipro Hexán Irt bétáin |
125,40 | Borostyánkösav |
103,10 | Hsdrosiproptl-tseíil-eellulőz 50 cP* |
5,20 | Aerostl 200*** |
0,30 | Magnéziarn-szföarát |
íö 10.00 | /iú$zó,y,yzeg / Ο'Λ’-ίΆ; |
1 8,00 | fisdroxípropd-metH-eelhdóz 15 cP* |
6.0Ö | Tiíán-dioxid |
6.00 | Oolzhlcí -gh«vol 100** |
30,Gö | Bívoíjí» részösszeg |
23 x 9,5 mm | Hosszúkás tabletta |
Mennyiség (mg) | Alkalmazott anyagok |
183,40 | Ciprofloxacijs hidrokktr id |
20,90 | Ciprofloxacijs bétám |
22,30 | Knliidon CL |
2,30 | Magnézmm-szteatát |
UÖ | Aerosil 200 |
230,00 | Rdszdss; eg / //?-rész |
151,40 | CiprofloxitcIn h idrokloriá |
232,10 | Cipsrofloxacin bétáin |
64,00 | BorostyáiskAsav |
52,30 | HklmxíptopikmetikccilakíZ. 15 cP |
7.60 | Magnéz iym -sateatát |
2.60 | Aerosil 200 |
510.00 | Aásrö.yyzeg / C/b-rém |
12,00 | HldTOxiprop5Í-meki-eeku.02 IS cP |
4,09 | i-V-iieiilén-glijtol 400 |
<00 | I'itan-dioxsd |
20,00 | : Bea·»?;»? í'ds2'<?,wreg ........ ....... |
19 x 8 mm | Hestzákás tabletta |
Mennyiség (mg) | Alkalmazott anyagok |
183,40 | Ciproíkíxacm fudrokloríd |
20,90 | Ciprofloxaent bétáin |
22,30 | Koltldon CL |
2,30 | Magnéziam-sztearát |
U0 | Aerosil 200 |
230,00 | rWrowtx g / <7? yt\v.· |
151,40 | Clprofloxaein hidrokkfíid |
232,10: | Ciprofl-uxacií'! bétáin |
65,10 | Bomstyáakösav |
73,00 | Hiámxipropil-meíiLceHnlóz 15 cP |
10,70 | Magnézíum-szteará; |
2,70 | Aerosii2öö |
.535,00 | Aé,»;fes',$zí;g / C7?-rész |
12,00 | Ht&oxipropu-íneüi-celtolóz 15 cF |
4,0(} | Poiietlléa-ghkol 3350 |
4,00 | Tfiáö-diöxid |
20,00 | Ftvoímt ráíró,yx.~a,g· |
19 x 8 mm | Hosszúkás tabletta |
Mennyiség (mg) | A lkait®ázott anyagok |
183,40 | C.proíloxxsr fodrok m ! |
20.90 | Cíp-fofexaem bétáin |
22.30 | Koílúlcn CL |
2.30 | Magnézium* szteat át |
1,10 | Aerosil 200 |
230,00 | Sbí.ríAsrcg (A-r L~ |
151,40 | CiproÜoxacin h JroJond |
232,10 | Clproöoxad» bétám |
64,00 | Borostyánkősav |
72,00 | í OíiroKÍprnpii-mdO-mOhjíóz 50 eP |
7,90 | Magnézmm-szíearát |
2,60 | Aerosll 200 |
530,(83 | tfásKtesőg / Cfo-rám |
12,00 | Hídmxlpropli-tnetÍl-ceilalóz i5cP |
4,00 | Polietiíén-gííkol 400 |
4,00 | Tslán-dioxid |
20,00 | btevonm mzö.y.sreg |
i 9 x 8 mm .......... ............. ............—- | Hosszúkás tabletta |
M«»bv iség (Rig) | Aíkahnazoít anyagok |
262.88 | öpraíloxacin bidrcklcnd |
29,80 | € '· profi öxscio bétám |
8.00 | Borostyánkösav |
42,20 | Koliidon CL |
130 | ÁerosilkOÖ |
5,30 | Magnéziutmsztearát |
350,00 | /íáfzóííreg / //í-m·.-: |
HM® | Cíproílnxac tn h tdrokiorid |
178,50 | Ciprníloxacin bétáin |
134,00 | Borostyánkősav |
87,88 | Hidjoxipropil-nxetil-celtoíá?. 15 cP |
2,70 | Aeresil 280 |
10,60 | Magnézsum-sztearát |
530,00 | /íászösxxug /<7A-«í5S |
12,00 | HiároKtpropiLtneitl-cellulóz 15 cP |
4,00 | Pniietí len-gl tkol 400 |
4,00 | rOán-dtexid |
20,00 | Savóm? zás»öS5aí5g· |
19x8 ·;ή | Hosszúkás tabletta |
Menny iség (mg) | AIkalmazott st ayagftfe |
183.40 | C: proli u\?.c tn b tdroklorid |
20,90 | Ciprotioxíiein benn» |
620 | Böfostyápkőssv: |
24,70 | Kolüánn Cl. |
1.20 | Aerosit 200 |
3,00 | Magnéziont-sztearáí |
240,(8) | /féss&wxreg / ZR-rdss |
151,40 | Ciproíloxaetn hidrokkmd |
232,10 | CtprofloxassH bétáin |
174,00 | Borostyánkősav |
95.70 | Hidrnxiprnpíl-ntebl-eelltíióz 15 cP |
3 ^O | AsroslS 200 |
'3 18 | M sgnöziníK-szlsarát |
670,00 | Péírávx^· / Olk-fihz |
12,08 | Hídroxipropü-menl-eelJiilóz 15 cP |
4,00 | Posísiiiéti-ghkol -K?Ö |
4.00 | Tkán-dioxid |
20,00 | 6;?v<?ft-ű/ í'éseő.wrey: |
19 x S maj | Hosszúkás tabletta |
Mennyiség (mg) | Alkalmazott anyagok |
357,00 | Clprofioxacia bétáin |
55,00 | KoBidon CL |
6,00 | Magnézsmn-sztsarát |
4,00 | Áerosi! 200 |
425,00 | /Oíveav.vres; ' !R-?c$z |
853,00 | Ciprolfexaein bétáin |
108,00 | BorostyánfeÖsav ......; ; ; . . > |
108,00 | Irt ia>\i >w 'il-met bed· i <;v 15 eO |
16,00 | Magnézium-sztemát |
10,00 | Aetosil 200 |
1075.00 | Résrúss'xvg· - CR-rész |
18,00 | Hiároxipropil-metü-celkilóz 15 cP |
6,00 | Po i ie ú lé f í-g 1 i ko 1400 |
6,00 | Thán-dioxid |
30,00 | Sevö/íaf rdszósaagg |
23 x 9,5 mm | Hosszúkás tahiét; a |
Mennyiség (mg) | Alkalmazott anyaguk |
357,00 | Ciptcfloxacín bétáin |
58.00 | Koíüdon CL |
6,00 | Magnézium- szieara; |
4,00 | Aerosil 200 |
425,80 | &brwir;?y / /fcrö: |
833,00 | CíproOoxactn belad |
108.00 | Borosiyúxíkősav |
108,00 | Hkiroxípropd-meíd-eeliuloz 3 cP |
15,00 | Magnézium-szteará· |
10,00 | Aerosil 200 |
1075,80 | /tészösszeg / í.’A-rész |
18,00 | Hldröxipropil-metil-eelhílé?, 15 eP |
6.00 | Pnhetdémglikot 400 |
6.00 | Titán-diösid |
30,00 | Aevow része»,vreg |
23 s 9,5 mm | Hosszúkás tabletta |
Claims (2)
- Szabadalmi igénypenink1. Onsiiísm adagolható, kmófes aníihintlkumöt tartalmazó ksszítmésty, azzal jellemezve, hogy tartalmazza az alábbiak keverékét: a) víz hatására mégduzzsdó pölitner ésb) legalább 'két kinoion antibiotikum származék keveréke, .X Az L Igénypont szerinti készítmény, aszal jellemezve, hogy a polimer vlszkozháza 5-488 x 18'J Pá.s <5-488 cP), 2 ;ömsg% vizes oldatba® 28°C hőmérsékleten mérve,3, V ' s no ' 'ge; \.ρο n-?e nt vStfu ?v va e,leme/v„ nyp -.omposAvAeft segédanyagot tartalmaz szerves savak, szétesést elősegítő anyagok, sikosiíó anyagok és kenőanyagok csoportjából megválasztva,4,. Az előző igénypontok bármelyike szerinti: készítmény, azzal jellemezve, hegy a készítmény egy gyors kioldódása részt (IR-rész) ás ev\ \cs elletett komxhu té-rt ^'R-rtszj kranmo keverékkeszitmény.5. Az előző igénypontok bármelyike szerinti készítmény, azzal jellemezve,. hogy az IR-rész kinofon anííbíotiknstöt, szétesést elősegítő anyagot, síkoslíó anyagot és kenőanyagot tartalmaz.ő. Az előző igénypontok bármelyike szerinti készítmény, azzal jellemezve, .hogy a CR-rész kinoion anttbloőkumot, polimert. szerves savat, sikosíló anyagot és kenőanyagot tartalmaz.?, A 4. igénypont szerinti készítmény, azzal jellemezve, begy az íR-tész kinoion antibiotikumot, szétesést elősegítő anyagot, síkositó anyagot és kenőanyagot tartalmaz, és a CR-rész kinoion antibiotikumok polimert, szerves savat, sikosltó anyagot és kenőanyagot tartalmaz.A A 4-2, igénypontok bármelyike szerinti készítmény, azzal jellemezve, hogy az IR-révz és a Ck-rész egyenként két kíhokss antibiotikum származék keverékét tártál» Azzá.9. A 4-8. igénypontok bármelyike szerinti készítmény, azzal jellemezve, bogy az IR-rész további komponensként szerves savat tartalmaz,18. A 4-9, igénypontok bármelyike szennt kes/méns kétrétegű tabletta tormájában,II. Az előző igénypontok bánne-vikc szenm <as/mrem, azzal jellemezve, hogy két kinelon anfibiotiknm származékának keverékeként egy es a szabad M’U Vvemket tartalmazza.i 2. Az előző igénypontok bármelyike szerinti: készítmény, azzal, jellemezve, hogy két kmoíon .aíjtibi&tiknffi származékának keverékekém két se keverékét tartalmazza.13. Az előző igénypontok bármelyike szerinti készítmény, azzal jellemezve, hogy á kinoion amíbiotikum cigroőoxaeln.1.4, Az előző igénypontok bármelyike szerinti készítmény, azzá! jellemezve, hogy a két származzék ciproRoxaein iridroklorló és eiprotlosaein bétáin.15. Az előző igénypont szerinti készlnoény, azzal jellemezve, hegy a clproíloxacm bidrokloríd es ciprefiosaein Maín tömegaránya 1:20-28:1.ló. Az előző igénypontok: bármelyike szerinti készítmény, azzal jellemezve, hogy a polimer poliszacbaridok, cellulózéterek és ezek .rtkáhíémsői, dortrfeek, dmdrán, pektinek, poliózok, gamlarábikorö, mánként, ksíragén, gafektomannánok, algrn, aígtnsav, slginátok, pölipepíídek, proteinek, kitlsszárínazékök, teljesen sztntetikss polimerek és ezek. ke verékei csoportjából: megválasztod.I7. Az előző igénypont szerinti Részlteérty, azzal jellemezve, hogy a polimer hidrexlpfopiímetib celluiőz.IS. Az előző igénypontok: bármelyike szerinti készítmény, azzal jellemezve, hogy 2-11): szenstomos és 1-4 karboxőosoportos szerves savat tartalmaz.19, Az előző igénypont .smristl készítmény, aszal jellemezve, hegy eceísav, malonsav, horöstyáítkősav, fesnarsav, horkősav és clítamsav csoportjából megválasztott szerv® savai, taríalötaz.20. Az előző Igénypontok h&rtnelyike szerinti készítmény, azzal jellemezve,. hogy szétesést elősegítő anyagkénttérhálós poiivinilpirrolidont ínrtalntaz,21. Az előző Igénypontok bármelyike szeritől készítmény, azzal jellemezve, hogy koliotdaiss szilteiem-dioxiő, hidrogénezett növényi olajok, szteáriusav, telkem és ezek keverékei közöl megválaszolt sikösííö anyagot tartalmaz,22, Az előző igénypontok btesolyike szerinti készibnény, .ami jellestezve, hogy kenőanyagként magaézhua-sztearátöÍ tartalmaz.23. Az előző igénypontok bármelyike szerinti készítmény, azzal jellemezve., hogy a polimer viszkozitása legfeljebb ?5x 10-> Pa.s (75 cP), 2 tömeg% vizes oldatban 2öeC hőmérsékleten mérve,24, Az eiozö igénypontok bármelyike szerinti készítmény, azzal jetietsezve, hogy a poífeer hiőtoxípropiimeth-celhdöz, amelynek viszkozitása legfeljebb 75x1 ö'-5 Pa.s (75 ePj, 2 tömeg% vizes oldatban 2Ö°C hőntérsékieíen átérve.
- 2.5. Az előző igénypont szerinti készítmény, azzal jellemezve, hogy a hidrolpropibsetll-cellulőz t -.'>0' tava legfeljebb *0\ 10'1\. s (>0 eP\ 2 íőntegj > s zva oldatban ~b<\? ro ne^ekkíen mén z26. .Az előző Igénypontok bármelyike szermti készítmény, azzal jellemezve, hogy 1 tömegrész polimerre vonatkoztatva 2-2Ö tötnegrész hatóanyag keveréketAariataax.27. Az előző igénypontok bármelyike .szerinti készítmény, azzal jellemezve, hogy polimerként hidroxipí’Opiintetiheeikílőzt tartalmaz és 1 tömegrész. hídroxípropíimetil-celluldzra vonatkoztatva 2-29 tStsegrész hatóanyag keveréket tartalmaz.28. Az előző igénypontok bármelyike szerinti készítmény, azaai jellemezve, hogy egyszeri dőztsíenpáhan 5ö(t-1000 mg kinolon antibiotikumot tartalmaz, bst&inrs számolva.29. Bljátás az előző: igénypontok bármelyike szerinti készítmény előállítására., azzal jellemezve, hogy s hatóanyag agy részét szétesést elősegítő anyaggal ke verjük,. granuláljuk, és síkositó anyaggal és keoőanyaggai keverjük t ÍR-rész), es a hatóan;, ag másik részét szerves savval és polimerrel keverjük, granuláljak és sikosltó anyaggal ás kenőanyaggai keverjük (CK-rész), és az ÍR- és CR-részeket kontblnáelős tahié» fernrájshan tahlettázzrtk és a kapott tablettákat adott esetben lakkozzak.39. Az előző igénypont szermti eljárás, azzal jellemezve., hogy a hatóanyag egy részét szétesést elősegítő anyaggal keverjük, graauialjak, és st'kosttő anyaggal és kesőasyaggal keverjük (IR-részy és a hatóanyag ntássk részét savval és hitkotdpropifetetlheelíaiózzál keverjük,, granuláljuk és síkosítő anyaggal és kenőanyaggal kevetjak (CR-rőszj, és az IR- és CR-részeket kombinációs tabletta formájában tehleházztsk és a kapott tablettákat adott esetben lakkozzuk.31, A 29. vagy 3ő. Igénypont szerinti eljárás, azzal jellemezve, begy az IR-részs: és a CR-részt kétrétegű tabletta íbmtajábsa iabfettázzak.32. A 29-31 ígéüypinuok bármelyike szerinti eljárás. azzal jellemezve, hogy az ÍR-részhez, szerves savat keverünk.33. Az előző igénypontok bármelyike szerinti készítmény, azzal jeíteiezve, hegy az USP XXIV száma kévérőlapáios tesztbest mind 0,1 N sósavban, mmind aeetátpuflérben 4.5 plhértéknél 50 l.'min ferdtdstszárnnál 37°C hőmérsékleten M éra időtartma alatt a hatóanyag 8ö %~s kioldódik.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10031043A DE10031043A1 (de) | 2000-06-26 | 2000-06-26 | Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung |
PCT/EP2001/006695 WO2002000219A1 (de) | 2000-06-26 | 2001-06-13 | Retard-zubereitungen von chinolon-antibiotika und verfahren zu ihrer herstellung |
Publications (3)
Publication Number | Publication Date |
---|---|
HUP0300953A2 HUP0300953A2 (hu) | 2003-08-28 |
HUP0300953A3 HUP0300953A3 (en) | 2009-04-28 |
HU229806B1 true HU229806B1 (en) | 2014-07-28 |
Family
ID=7646816
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0300953A HU229806B1 (en) | 2000-06-26 | 2001-06-13 | Orally dosable sustained-release compositions of quinolone antibiotics and method for preparation thereof |
Country Status (41)
Country | Link |
---|---|
US (3) | US7709022B2 (hu) |
EP (1) | EP1296685B1 (hu) |
JP (1) | JP4958373B2 (hu) |
KR (1) | KR100939617B1 (hu) |
CN (1) | CN1273138C (hu) |
AR (1) | AR029688A1 (hu) |
AT (1) | ATE355062T1 (hu) |
AU (1) | AU2001270573A1 (hu) |
BG (1) | BG65914B1 (hu) |
BR (1) | BRPI0111911B8 (hu) |
CA (1) | CA2414271C (hu) |
CU (1) | CU23264B7 (hu) |
CY (1) | CY1107574T1 (hu) |
CZ (1) | CZ301812B6 (hu) |
DE (2) | DE10031043A1 (hu) |
DK (1) | DK1296685T3 (hu) |
DO (1) | DOP2001000199A (hu) |
EE (1) | EE04992B1 (hu) |
ES (1) | ES2282270T3 (hu) |
GT (1) | GT200100126A (hu) |
HK (1) | HK1058479A1 (hu) |
HN (1) | HN2001000132A (hu) |
HR (1) | HRP20030050B1 (hu) |
HU (1) | HU229806B1 (hu) |
IL (2) | IL153333A0 (hu) |
MA (1) | MA25761A1 (hu) |
MX (1) | MXPA02012727A (hu) |
MY (1) | MY140994A (hu) |
NO (1) | NO325415B1 (hu) |
NZ (1) | NZ523352A (hu) |
PE (1) | PE20020207A1 (hu) |
PL (1) | PL203710B1 (hu) |
PT (1) | PT1296685E (hu) |
RU (1) | RU2332204C2 (hu) |
SI (1) | SI1296685T1 (hu) |
SK (1) | SK287384B6 (hu) |
SV (1) | SV2002000505A (hu) |
TW (1) | TWI279232B (hu) |
UA (1) | UA83616C2 (hu) |
WO (1) | WO2002000219A1 (hu) |
ZA (1) | ZA200210350B (hu) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10031043A1 (de) * | 2000-06-26 | 2002-02-14 | Bayer Ag | Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung |
WO2004000924A1 (en) * | 2002-06-25 | 2003-12-31 | Micro Science Tech Co., Ltd. | Polymer resin formulation having anti-microbial or anti-cogulability and preparation method thereof |
BRPI0407368A (pt) * | 2003-02-10 | 2006-02-14 | Bayer Healthcare Ag | tratamento de doenças bacterianas dos órgãos respiratórios mediante aplicação local e fluor-quinolonas. |
WO2004073729A1 (ja) | 2003-02-21 | 2004-09-02 | Translational Research Ltd. | 薬物の経鼻投与用組成物 |
KR100974482B1 (ko) | 2003-03-27 | 2010-08-10 | 가부시키가이샤 바이오악티스 | 비강용 분말 약제 투약 장치 |
CA2532714C (en) | 2003-08-04 | 2010-11-16 | Kyorin Pharmaceutical Co., Ltd. | Oral sustained-release tablet comprising 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide |
US7943585B2 (en) * | 2003-12-22 | 2011-05-17 | Sandoz, Inc. | Extended release antibiotic composition |
WO2006007323A2 (en) * | 2004-06-28 | 2006-01-19 | Alza Corporation | Dosage forms for low solubility and/or low dissolution rate free acid pharmaceutical agents |
US20080206329A1 (en) * | 2004-12-03 | 2008-08-28 | Sanjay Verma | Modified Release Ciprofloxacin Compositions |
DK1868581T3 (da) * | 2005-04-11 | 2012-07-09 | Abbott Lab | Farmaceutiske sammensætninger med forbedrede opløsningsprofiler til dårligt opløselige lægemidler |
DE602006012962D1 (de) * | 2006-07-19 | 2010-04-29 | Tabuk Pharmaceutical Mfg Co | Pharmazeutische Zubereitungen von Ciprofloxacin |
JP5415769B2 (ja) | 2006-12-26 | 2014-02-12 | 株式会社新日本科学 | 経鼻投与用製剤 |
WO2009117130A2 (en) * | 2008-03-21 | 2009-09-24 | Mylan Pharmaceuticals, Inc. | Extended release forumulation containing a wax |
BRPI1007945C8 (pt) * | 2009-02-13 | 2021-05-25 | Romark Laboratories Lc | formulação farmacêutica de liberação controlada de nitazoxanida, tizoxanida ou uma combinação dos mesmos, e, comprimido de bicamada para administração oral |
WO2010131486A1 (en) * | 2009-05-15 | 2010-11-18 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal pharmaceutical compositions with improved pharmacokinetics |
US11033624B2 (en) * | 2010-06-02 | 2021-06-15 | Novaflux Inc. | Medical item for prevention and treatment of ear infection |
CN102247313A (zh) * | 2010-06-11 | 2011-11-23 | 北京润德康医药技术有限公司 | 一种以莫西沙星为活性成分的口服缓释固体制剂 |
US10285865B2 (en) | 2014-05-02 | 2019-05-14 | Novaflux Inc. | Drug-releasing device usable in mucosal body cavities |
US11744967B2 (en) | 2017-09-26 | 2023-09-05 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal delivery devices |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2951792A (en) * | 1959-11-18 | 1960-09-06 | Smith Kline French Lab | Sustained release pharmaceutical tablets |
FR2100858B1 (hu) | 1970-07-03 | 1975-06-06 | Daiichi Seiyaku Co | |
US4122157A (en) | 1977-03-04 | 1978-10-24 | Richardson-Merrell Inc. | Nitrofurantoin sustained release tablet |
US4293539A (en) * | 1979-09-12 | 1981-10-06 | Eli Lilly And Company | Controlled release formulations and method of treatment |
FR2470599A1 (fr) * | 1979-12-07 | 1981-06-12 | Panoz Donald | Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus |
DE3142854A1 (de) | 1981-10-29 | 1983-05-11 | Bayer Ag, 5090 Leverkusen | 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7-piperazino-chinolin-3-carbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel |
US4370313A (en) * | 1981-10-26 | 1983-01-25 | Eaton Laboratories, Inc. | Nitrofurantoin dosage form |
US4369172A (en) * | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
US4530928A (en) * | 1982-01-13 | 1985-07-23 | Merck & Co., Inc. | Quinoline carboxylic acid complexes with guanidinium carbonate |
US4440740A (en) * | 1982-04-26 | 1984-04-03 | Merck & Co., Inc. | α-Keto aldehydes as enhancing agents of gastro-intestinal drug absorption |
US4443428A (en) * | 1982-06-21 | 1984-04-17 | Euroceltique, S.A. | Extended action controlled release compositions |
IT1198386B (it) | 1982-07-06 | 1988-12-21 | Lepetit Spa | Un prodotto a rilascio protratto contenente il suloctidile |
IL70071A (en) | 1982-11-01 | 1987-12-31 | Merrell Dow Pharma | Multilayered sustained release pharmaceutical tablets having non-uniform distribution of active ingredient |
US4478822A (en) * | 1983-05-16 | 1984-10-23 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
US4639458A (en) * | 1985-01-22 | 1987-01-27 | Merck & Co., Inc. | Tablet and formulation |
NL8500724A (nl) * | 1985-03-13 | 1986-10-01 | Univ Groningen | Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan. |
FR2585246A1 (fr) * | 1985-07-26 | 1987-01-30 | Cortial | Procede d'obtention de formes pharmaceutiques solides a liberation prolongee |
US5188840A (en) * | 1985-09-26 | 1993-02-23 | Chugai Seiyaku Kabushiki Kaisha | Slow-release pharmaceutical agent |
US4734285A (en) * | 1985-10-28 | 1988-03-29 | The Dow Chemical Company | Sustained release compositions |
IT1188212B (it) * | 1985-12-20 | 1988-01-07 | Paolo Colombo | Sistema per il rilascio a velocita' controllata di sostanze attive |
US5286754A (en) * | 1986-01-21 | 1994-02-15 | Bayer Aktiengesellschaft | Pharmaceutical formulations of ciprofloxacin |
DE3601566A1 (de) * | 1986-01-21 | 1987-07-23 | Bayer Ag | Pharmazeutische zubereitungen von ciprofloxacin |
JPS62195323A (ja) * | 1986-02-24 | 1987-08-28 | Eisai Co Ltd | 胃内滞留型粒子 |
ATE71293T1 (de) | 1986-09-18 | 1992-01-15 | London Pharmacy Innovation | Arzneiformulierung. |
US4869908A (en) * | 1987-01-09 | 1989-09-26 | K.V. Pharmaceutical Co. | Fibre formulations |
US4786503A (en) * | 1987-04-06 | 1988-11-22 | Alza Corporation | Dosage form comprising parallel lamine |
US5200193A (en) * | 1987-04-22 | 1993-04-06 | Mcneilab, Inc. | Pharmaceutical sustained release matrix and process |
DE3720757A1 (de) * | 1987-06-24 | 1989-01-05 | Bayer Ag | Dhp-manteltablette |
US5472710A (en) * | 1988-04-16 | 1995-12-05 | Schwarz Pharma Ag | Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture |
US5032406A (en) * | 1989-02-21 | 1991-07-16 | Norwich Eaton Pharmaceuticals, Inc. | Dual-action tablet |
US5007790A (en) * | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
US5085865A (en) * | 1989-04-12 | 1992-02-04 | Warner-Lambert Company | Sustained release pharmaceutical preparations containing an analgesic and a decongestant |
DK469989D0 (da) * | 1989-09-22 | 1989-09-22 | Bukh Meditec | Farmaceutisk praeparat |
IT1237904B (it) * | 1989-12-14 | 1993-06-18 | Ubaldo Conte | Compresse a rilascio a velocita' controllata delle sostanze attive |
JPH0624959A (ja) * | 1991-10-04 | 1994-02-01 | Bayer Yakuhin Kk | 胃内浮遊型薬物徐放性固形製剤 |
DE4200821A1 (de) * | 1992-01-15 | 1993-07-22 | Bayer Ag | Geschmacksmaskierte pharmazeutische mittel |
JP2958731B2 (ja) * | 1992-02-14 | 1999-10-06 | 日本特殊陶業株式会社 | 酸化アルミニウム基焼結体及びその製造方法 |
US5582837A (en) * | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
IT1255522B (it) * | 1992-09-24 | 1995-11-09 | Ubaldo Conte | Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita' |
IT1256393B (it) * | 1992-11-17 | 1995-12-04 | Inverni Della Beffa Spa | Forme matriciali multistrato per il rilascio controllato di principi attivi |
JP2686215B2 (ja) | 1993-04-28 | 1997-12-08 | 信越化学工業株式会社 | 徐放性錠剤 |
IT1264696B1 (it) | 1993-07-09 | 1996-10-04 | Applied Pharma Res | Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata |
DE4406424A1 (de) * | 1994-02-28 | 1995-08-31 | Bayer Ag | Expandierbare Arzneiformen |
US5464633A (en) * | 1994-05-24 | 1995-11-07 | Jagotec Ag | Pharmaceutical tablets releasing the active substance after a definite period of time |
US5900425A (en) * | 1995-05-02 | 1999-05-04 | Bayer Aktiengesellschaft | Pharmaceutical preparations having controlled release of active compound and processes for their preparation |
CN1048628C (zh) | 1995-07-06 | 2000-01-26 | 东北制药总厂 | 环丙沙星注射液的制备方法 |
US5705190A (en) * | 1995-12-19 | 1998-01-06 | Abbott Laboratories | Controlled release formulation for poorly soluble basic drugs |
IT1282650B1 (it) * | 1996-02-19 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici |
US5972389A (en) * | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
US5891474A (en) * | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
PT998271E (pt) * | 1997-06-06 | 2005-10-31 | Depomed Inc | Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis |
IN186245B (hu) * | 1997-09-19 | 2001-07-14 | Ranbaxy Lab Ltd | |
PL192273B1 (pl) * | 1997-09-25 | 2006-09-29 | Bayer Ag | Preparat środka leczniczego w postaci pastylki o kontrolowanej dyfuzji lub w postaci układu matrycowego, o kontrolowanym uwalnianiu substancji czynnej |
PA8466701A1 (es) * | 1998-01-21 | 2000-09-29 | Pfizer Prod Inc | Comprimido de mesilato de trovafloxacino |
SK285478B6 (sk) | 1998-09-14 | 2007-02-01 | Ranbaxy Laboratories Limited | Jednodenná formulácia na orálne podanie na kontrolované uvoľňovanie ciprofloxacínu |
MXPA02004413A (es) | 1999-11-02 | 2002-09-02 | Depomed Inc | Induccion farmacologica del modo de alimentacion, para la administracion aumentada de drogas al estomago. |
MXPA02007254A (es) | 2000-02-04 | 2002-12-09 | Depomed Inc | Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero. |
US6488962B1 (en) | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
DE10031043A1 (de) * | 2000-06-26 | 2002-02-14 | Bayer Ag | Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung |
US6780057B2 (en) * | 2001-12-21 | 2004-08-24 | Intel Corporation | Coaxial dual pin sockets for high speed I/O applications |
-
2000
- 2000-06-26 DE DE10031043A patent/DE10031043A1/de not_active Ceased
-
2001
- 2001-06-13 SI SI200130710T patent/SI1296685T1/sl unknown
- 2001-06-13 AU AU2001270573A patent/AU2001270573A1/en not_active Abandoned
- 2001-06-13 JP JP2002505001A patent/JP4958373B2/ja not_active Expired - Lifetime
- 2001-06-13 CN CNB018118283A patent/CN1273138C/zh not_active Expired - Lifetime
- 2001-06-13 IL IL15333301A patent/IL153333A0/xx unknown
- 2001-06-13 UA UA2003010650A patent/UA83616C2/uk unknown
- 2001-06-13 WO PCT/EP2001/006695 patent/WO2002000219A1/de active IP Right Grant
- 2001-06-13 NZ NZ523352A patent/NZ523352A/en not_active IP Right Cessation
- 2001-06-13 CA CA002414271A patent/CA2414271C/en not_active Expired - Lifetime
- 2001-06-13 KR KR1020027017634A patent/KR100939617B1/ko active IP Right Grant
- 2001-06-13 DE DE50112123T patent/DE50112123D1/de not_active Expired - Lifetime
- 2001-06-13 PL PL360632A patent/PL203710B1/pl unknown
- 2001-06-13 EE EEP200200707A patent/EE04992B1/xx unknown
- 2001-06-13 RU RU2003102365/15A patent/RU2332204C2/ru active
- 2001-06-13 US US10/311,913 patent/US7709022B2/en not_active Expired - Fee Related
- 2001-06-13 ES ES01949412T patent/ES2282270T3/es not_active Expired - Lifetime
- 2001-06-13 MX MXPA02012727A patent/MXPA02012727A/es active IP Right Grant
- 2001-06-13 PT PT01949412T patent/PT1296685E/pt unknown
- 2001-06-13 CZ CZ20024216A patent/CZ301812B6/cs not_active IP Right Cessation
- 2001-06-13 BR BRPI0111911A patent/BRPI0111911B8/pt not_active IP Right Cessation
- 2001-06-13 AT AT01949412T patent/ATE355062T1/de active
- 2001-06-13 EP EP01949412A patent/EP1296685B1/de not_active Expired - Lifetime
- 2001-06-13 SK SK1821-2002A patent/SK287384B6/sk not_active IP Right Cessation
- 2001-06-13 HU HU0300953A patent/HU229806B1/hu unknown
- 2001-06-13 DK DK01949412T patent/DK1296685T3/da active
- 2001-06-25 SV SV2001000505A patent/SV2002000505A/es active IP Right Grant
- 2001-06-25 HN HN2001000132A patent/HN2001000132A/es unknown
- 2001-06-25 MY MYPI20012975A patent/MY140994A/en unknown
- 2001-06-26 AR ARP010103034A patent/AR029688A1/es not_active Application Discontinuation
- 2001-06-26 GT GT200100126A patent/GT200100126A/es unknown
- 2001-06-26 PE PE2001000618A patent/PE20020207A1/es active IP Right Grant
- 2001-06-26 TW TW090115340A patent/TWI279232B/zh not_active IP Right Cessation
- 2001-06-26 DO DO2001000199A patent/DOP2001000199A/es unknown
-
2002
- 2002-12-09 IL IL153333A patent/IL153333A/en active IP Right Grant
- 2002-12-11 BG BG107372A patent/BG65914B1/bg unknown
- 2002-12-20 NO NO20026160A patent/NO325415B1/no not_active IP Right Cessation
- 2002-12-20 ZA ZA200210350A patent/ZA200210350B/en unknown
- 2002-12-24 CU CU20020333A patent/CU23264B7/es unknown
- 2002-12-26 MA MA26979A patent/MA25761A1/fr unknown
-
2003
- 2003-01-24 HR HR20030050A patent/HRP20030050B1/xx not_active IP Right Cessation
-
2004
- 2004-02-23 HK HK04101286A patent/HK1058479A1/xx not_active IP Right Cessation
-
2006
- 2006-11-16 US US11/560,594 patent/US7780986B2/en not_active Expired - Fee Related
-
2007
- 2007-04-04 CY CY20071100478T patent/CY1107574T1/el unknown
- 2007-06-14 US US11/762,831 patent/US8187632B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210008063A1 (en) | Oxymorphone controlled release compositions | |
HU229806B1 (en) | Orally dosable sustained-release compositions of quinolone antibiotics and method for preparation thereof | |
EP0188040B1 (en) | Slow release solid preparation | |
EP1340495B1 (en) | Extended release tablet of clarithromycin | |
CA2592173C (en) | Controlled release complex formulation for oral administration of medicine for diabetes and method for the preparation thereof | |
EP1351668B1 (en) | Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles | |
CN106943355B (zh) | 药物组合物 | |
JP2003534269A (ja) | 水溶性とそれ以外の活性物質の放出制御錠剤およびその方法 | |
KR20130086128A (ko) | 복용 용이성 고형 제제 | |
JP6449451B2 (ja) | メトホルミン徐放性製剤及びその製造方法 | |
JP2018118966A (ja) | 3位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。 | |
EP1763338B1 (en) | Oral sustained release formulation of tedisamil with gastric retention properties | |
KR20180127951A (ko) | 바레니클린 서방성 제제 및 이의 제조 방법 | |
KR101485421B1 (ko) | 이토프라이드 염산염을 함유하는 제어 방출성 경구 제제의 조성물 및 그의 제조방법 | |
JP3182423B2 (ja) | シサプリドの経口用徐放性組成物 | |
US8343544B2 (en) | Oral sustained-release tablet | |
CA2493593A1 (en) | Bicifadine formulation | |
EP3760190B1 (en) | Controlled-release tablets of pregabalin, method of making, and method of use thereof | |
WO2005018618A1 (en) | Formulation of stable for moisture absorption and quickly dissolved tablet containing cefuroxime axetil and it's manufacturing process | |
RU2603469C2 (ru) | Таблетка с контролируемым высвобождением для перорального введения и способ ее приготовления | |
TW201343201A (zh) | 持續釋放型口服固體製劑 | |
WO2023089553A1 (en) | Controlled release formulations of flavoxate and process for preparation thereof | |
CN112137978A (zh) | 一种胃保留改性释放的固体药物组合物、制备方法及应用 | |
CN112641744A (zh) | 一种交沙霉素薄膜衣片及其制备方法 | |
WO2008038106A1 (en) | Venlafaxine extended release formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB9A | Succession in title |
Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE Free format text: FORMER OWNER(S): BAYER AG., DE; BAYER HEALTHCARE AG., DE |
|
HC9A | Change of name, address |
Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE Free format text: FORMER OWNER(S): BAYER AG., DE; BAYER HEALTHCARE AG., DE; BAYER PHARMA AKTIENGESELLSCHAFT, DE; BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE |
|
GB9A | Succession in title |
Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE Free format text: FORMER OWNER(S): BAYER AG., DE; BAYER HEALTHCARE AG., DE; BAYER PHARMA AKTIENGESELLSCHAFT, DE; BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE |